ROS1+ NSCLC Treatment Choices for First-Line and Beyond

How Molecular Test Results and Delays Influence Treatment in NSCLC

During a Case-Based Roundtable® event, Julia Rotow, MD, continued a discussion on how biomarker testing for patients with non–small cell lung cancer impacts treatment decisions in the second article of a 2-part series.

Discussing Non-Clinical Barriers to NGS Testing for NSCLC

During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.

Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC

During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.

Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC

In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.

Velcheti Addresses Promising Data with Repotrectinib in ROS1+ NSCLC

In the first article of a 2-part series, Vamsidhar Velcheti, MD, MBA, discussed why patients with lung cancer may experience dizziness with repotrectinib and why the efficacy data behind this therapy are considered impressive.

Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC

Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.

Repotrectinib Shows Frontline Responses in ROS1+ Advanced NSCLC

Patrick Forde, MBBCh, discusses the results of the TRIDENT-1 trial that led to the approval of repotrectinib for patients with metastatic ROS1 positive NSCLC.